TOKYO -- Japanese drugmakers Shionogi and Daiichi Sankyo look to ensure that their vaccines under development will be effective against the new omicron variant of the coronavirus.
Shionogi is considering making an active vaccine ingredient based on the omicron virus' genetic information. The company has been developing a vaccine against previous coronavirus variants which will soon enter final-stage clinical trials, with plans to go on the market by March.
